Dr. Faderl is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3170 Porter Drive
Palo Alto, CA 94304
Education & Training
- University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1996 - 1999
- Steward Carney HospitalResidency, Internal Medicine, 1993 - 1996
- Ludwig Maximilian University of Munich Faculty of MedicineClass of 1990
Certifications & Licensure
- TX State Medical License 1999 - 2025
- NJ State Medical License 2013 - 2017
- American Board of Internal Medicine Internal Medicine
Clinical Trials
- Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies Start of enrollment: 2001 Sep 06
- Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome Start of enrollment: 2003 Jun 23
- Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML) Start of enrollment: 2003 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- 173 citationsEpigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemiaAlfonso Quintás-Cardama, Farhad Ravandi, Theresa Liu-Dumlao, Mark Brandt, Stefan Faderl
Blood. 2012-12-06 - 229 citationsImatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.Hagop M. Kantarjian, Jorge E. Cortes, Susan O'Brien, Francis Giles, M. Albitar
Blood. 2002-05-15 - 35 citationsA pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phaseAlfonso Quintás-Cardama, Hagop M. Kantarjian, Guillermo Garcia-Manero, Susan O'Brien, Stefan Faderl
Leukemia & Lymphoma. 2007-02-01
Abstracts/Posters
- Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylatin...Stefan Faderl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 ...Stefan Faderl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloi...Stefan Faderl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observati...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
- John Theurer Cancer Center (JTCC) Researchers to Present 52 Abstracts Across Hematological Malignancies at the 2020 American Society of Hematology (ASH) Annual Meeting and ExpositionDecember 4th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: